Overview

Arginase Inhibition in Humans With Obesity

Status:
Completed

Trial end date:
2022-03-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the efficacy of arginase inhibition on endothelial function in humans with obesity.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Karolinska Institutet

Criteria

Inclusion Criteria:

BMI >35kg/m2

Exclusion Criteria:

Age >80 years. Type 2 diabetes defined as >7 mmol/L in fasting plasma glucose or >11 mmol/L
following 2h of oral glycemic load.

Myocardial infarction/unstable angina within 6 weeks prior to the study. Treatment with
oral anticoagulants (Warfarin or New oral anticoagulants), Raynaud's phenomenon, peripheral
vasculopathies, arterial shunting or other vascular surgery of the study arm.

Any concomitant disease or condition that may interfere with the possibility for the
patient to comply with or complete the study protocol.

Participant in an ongoing study. Unwillingness to participate following oral and written
information.